Rescuing a Fragment: How a Dutch Discovery and a Russian Tail Produced Semax

Some peptides are discovered. Others are designed, and the best designs usually begin with a puzzle. Semax is a good example of the second kind: its history is the story of taking a biologically interesting but fragile piece of a hormone, and engineering it to survive.

The hormone and its fragments

ACTH, adrenocorticotropic hormone, is a 39-amino-acid peptide released by the pituitary gland. Its best-known job is to tell the adrenal glands to produce cortisol. But ACTH belongs to a family of peptides, the melanocortins, that are all cut from the same large precursor protein, and shorter pieces of it have effects of their own.

In the 1950s and 1960s, the Dutch pharmacologist David de Wied at the University of Utrecht was studying how the pituitary affects behavior. He noticed that rats whose pituitaries had been removed learned avoidance tasks more slowly than normal rats, and that treating them with pituitary extracts restored the learning. When he narrowed down the active material, a surprising result emerged: ACTH fragments that were far too short to stimulate the adrenal glands still influenced behavior in his tests. In particular, the stretch of ACTH between residues 4 and 10, ACTH(4–10), with the sequence Met-Glu-His-Phe-Arg-Trp-Gly, kept the behavioral effects reported by his group while having essentially no corticosteroid-releasing activity.

That separation, behavior without the stress hormone, was the seed of a long line of neuropeptide research.

The problem with a small peptide

ACTH(4–10) is a heptapeptide, and heptapeptides in blood and tissue are on a short fuse. Enzymes called peptidases attack them from both ends and from the middle. Research groups found that the fragment’s biological effects lasted only a short time, and the intact peptide was cleared quickly. If you want a peptide to be useful as an experimental tool, a half-life measured in minutes is a serious limitation.

The Russian solution

In the 1980s, scientists at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, working in the school of Ignatiy Ashmarin and with the chemist Nikolay Myasoedov, tackled the stability problem by chemical design. Their idea was to keep the part of ACTH(4–10) believed to carry the activity, Met-Glu-His-Phe, and replace the vulnerable C-terminal end, Arg-Trp-Gly, with Pro-Gly-Pro.

The resulting heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, is Semax.

Why Pro-Gly-Pro? Proline has a rigid ring structure that constrains the peptide backbone and makes the bonds around it harder for many peptidases to cut. A Pro-Gly-Pro tail at the end acts like a protective cap. It also happens that Pro-Gly-Pro is itself a naturally occurring tripeptide that appears as a breakdown product of collagen and has been the subject of its own studies, so it was not a foreign structure.

The design logic generalizes: if a bioactive fragment is fragile, try to protect the ends with residues that proteases dislike, such as proline, D-amino acids or capping groups.

What was studied afterward

Following the original design, the Moscow group and others examined Semax in a variety of experimental systems, mostly rodent models of learning, memory and stress, models of cerebral ischemia, and cell-culture work. Some of the more discussed lines of work looked at effects on brain-derived neurotrophic factor and its receptor, and at changes in gene expression in brain tissue after administration. Because much of this literature originates from a small number of institutions and was published in a mix of Russian and international journals, some of it has not been independently replicated at scale. Semax has regulatory status as a medication in Russia and some neighboring countries, but that status says nothing about research reagents sold elsewhere, and it should not be read as evidence about any particular use.

Lessons for the researcher

There are a few practical takeaways from the Semax story.

1. Origin determines context. Semax is an analog designed from an ACTH fragment, and its biology is best read against the melanocortin literature, not as a generic “nootropic.”
2. Stability is part of the design, not an afterthought. If you are studying a peptide in plasma or tissue, measure its half-life in your system rather than assuming it.
3. Check the sequence. For a heptapeptide with a distinctive Pro-Gly-Pro tail, the mass-spectrometry identity on the certificate of analysis is a simple, definitive check.
4. Read the lineage of papers. Knowing which institution produced which finding helps you judge independence of evidence.

A good scientific habit is to ask of any peptide: what problem was it built to solve? For Semax, the answer is a long and instructive one.

For researchers working with Semax, the specifications and batch certificate of analysis are on the Semax 10mg product page.

All Lucid Aminos products are sold strictly for laboratory research use. They are not drugs, dietary supplements or food, and they are not for human or veterinary use. This article is educational, describes published research, and is not medical advice.